This widening deficit primarily reflects an increase in operating expenses, with general and administrative costs rising by EUR 34.7M to EUR 67.7M, and R&D spending increasing by EUR 31.2M to EUR 177.8M.

The biotech firm held cash, cash equivalents, and short-term investments of EUR 530.4M at the end of 2025, providing a projected cash runway through the fourth quarter of 2027 based on current operating assumptions.

"With a solid cash position, we are well-positioned to execute our strategic priorities and prepare for the future," stated CEO Marc de Garidel, also highlighting the company's recent progress.

Abivax reported that the meeting of the independent Data Safety Monitoring Board (DSMB) for the Phase 3 ABTECT study, held on March 18, identified no new safety signals.

This positive update supports the continued advancement of the program, with the company remaining on track to release results from its ABTECT-UC maintenance trials at the end of the second quarter of 2026.

Finally, Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer, bringing extensive expertise in IBD to support the company's next phase of growth.